Head-To-Head Contrast: Cadrenal Therapeutics (CVKD) & Its Rivals

Cadrenal Therapeutics (NASDAQ:CVKD) is one of 988 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Cadrenal Therapeutics to related businesses based on the strength of its earnings, dividends, risk, analyst recommendations, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for Cadrenal Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	0	0	2	0	3.00
Cadrenal Therapeutics Competitors	6184	18552	44227	910	2.57

Cadrenal Therapeutics presently has a consensus price target of $3.50, indicating a potential upside of 759.32%. As a group, “Pharmaceutical preparations” companies have a potential upside of 80.56%. Given Cadrenal Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Cadrenal Therapeutics is more favorable than its peers.

Insider and Institutional Ownership

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 58.1% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Cadrenal Therapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics’ peers have a beta of 0.85, indicating that their average stock price is 15% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cadrenal Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	-$8.36 million	-0.59
Cadrenal Therapeutics Competitors	$2.15 billion	$149.20 million	-4.23

Cadrenal Therapeutics’ peers have higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Cadrenal Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-128.67%	-117.76%
Cadrenal Therapeutics Competitors	-2,601.54%	-229.25%	-29.53%

Summary

Cadrenal Therapeutics beats its peers on 8 of the 13 factors compared.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.